Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.24.1.1.u2
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Product Information [Line Items]    
Total net revenue $ 2,406,391 $ 921
Health Care, Patient Service [Member]    
Product Information [Line Items]    
Total net revenue [1] 2,149,049
Histology Fees [Member]    
Product Information [Line Items]    
Total net revenue 237,972
Health Care, Other [Member]    
Product Information [Line Items]    
Total net revenue 16,058
Department of Defense Observational Studies [Member]    
Product Information [Line Items]    
Total net revenue 2,885
Other Revenues [Member]    
Product Information [Line Items]    
Total net revenue [2] $ 427 $ 921
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test.
[2] Other revenues include pre-acquisition CyPath® Lung royalty income and laboratory services.